HC Wainwright Reaffirms Buy Rating for IRD
HC Wainwright maintains a buy rating on IRD, targeting $8 per share, a 93.24% upside from the current price.
Key Points
- On June 17, 2026, HC Wainwright reiterated its buy rating on IRD, setting a price target of $8.
- HC Wainwright's $8 price target implies 93.24% upside from Opus Genetics, Inc.'s ($IRD) current $4.14 share price.
- IRD shares are trading around $3.95, with recent insider sales including 1.7 million shares by the Foundation Fighting Blindness.
- Other analysts like Guggenheim and Leerink Partners have also rated IRD as a buy, with targets up to $16.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, HC Wainwright reaffirmed its buy rating on IRD, setting a price target of $8. The analyst behind the decision, Matthew Caufield, believes in the stock's potential for growth. Currently, IRD shares are trading around $3.95.
Other Institutional Activity in IRD
Several institutional investors have made moves regarding IRD. Caligan Partners LP established a position with 6,075,028 shares valued at approximately $27.6 million. Adage Capital Partners GP, L.L.C. increased its holdings by 4,924,779 shares, bringing its total to 6,029,775 shares worth about $27.4 million. Meanwhile, Millennium Management LLC added 627,882 shares, ending with 2,630,432 shares valued at around $11.97 million.
Opus Genetics, Inc. Stock Up 12.2%
IRD shares are trading near $3.95. While the company lacks a published P/E ratio, the stock's 52-week range and other financial metrics like moving averages are not provided, indicating a need for further financial analysis to assess its volatility and market position.
Insider Buying and Selling at Opus Genetics, Inc.
Insider transactions have been active at IRD. On May 18, 2026, the Foundation Fighting Blindness Retinal Degeneration Fund sold 1,700,000 shares at an average price of $4.35. Earlier, on April 23, several executives, including Chief Scientific & Development Officer Jayagopal Ashwath and CEO George Magrath, sold shares at prices around $5.19 to $5.24.
Analysts Set New Price Targets
HC Wainwright is not alone in its bullish outlook for IRD. On June 4, 2026, Guggenheim initiated coverage with a buy rating and a $16 target. Leerink Partners also began coverage on May 21, setting a buy rating with a $10 target. The consensus among analysts is positive, with a general buy recommendation and various price targets reflecting confidence in IRD's future prospects.
About IRD
IRD operates in a competitive sector, focusing on innovative solutions. While specific details about its headquarters, CEO, and employee count are not provided, the company's strategic initiatives and market activities suggest a focus on growth and development.
Bottom Line
HC Wainwright's reiteration of a buy rating with an $8 target on IRD reflects optimism in its growth potential. Investors and analysts alike are keeping a close eye on IRD's performance, considering recent institutional activity and insider sales. As with all 13F filings and analyst ratings, these insights are based on past data and expectations, and investors should consider the broader market context.
Get Opus Genetics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IRD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.